Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.


Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 25 3 2019
medline: 25 3 2019
entrez: 24 3 2019
Statut: ppublish

Résumé

In the original version of this article the authors noted an omission in the author affiliations where the university details: Queen Mary University of London was not included in the original affiliation for the majority of the authors. The correct affiliations are as follows1. Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK3. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK6. Evolution and Cancer Laboratory, Barts Cancer Institute, Queen Mary University of London, London, UK.

Identifiants

pubmed: 30903015
doi: 10.1038/s41375-019-0425-9
pii: 10.1038/s41375-019-0425-9
pmc: PMC7608209
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

1540

Commentaires et corrections

Type : ErratumFor

Auteurs

Shamzah Araf (S)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. s.araf@qmul.ac.uk.
Centre for Genomic Health, Queen Mary University of London, London, UK. s.araf@qmul.ac.uk.

Jun Wang (J)

Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Koorosh Korfi (K)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Celine Pangault (C)

UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France.

Eleni Kotsiou (E)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Ana Rio-Machin (A)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Tahrima Rahim (T)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

James Heward (J)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Andrew Clear (A)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Sameena Iqbal (S)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Jeff K Davies (JK)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Peter Johnson (P)

Cancer Sciences Unit, Cancer Research UK Centre, Southampton, UK.

Maria Calaminici (M)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Silvia Montoto (S)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Rebecca Auer (R)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Claude Chelala (C)

Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

John G Gribben (JG)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Trevor A Graham (TA)

Evolution and Cancer Laboratory, Barts Cancer Institute, Queen Mary University of London, London, UK.

Thierry Fest (T)

UMR INSERM 1236, Université de Rennes, 1, EFS de Bretagne, CHU de Rennes, Rennes, France.

Jude Fitzgibbon (J)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.

Jessica Okosun (J)

Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. j.okosun@qmul.ac.uk.

Classifications MeSH